2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Portfolio Pulse from
The gene-editing sector experienced a strong start in 2024 with the FDA approval of Casgevy, a CRSPR-based gene therapy for sickle cell anemia developed by Vertex Pharmaceuticals. However, the sector's momentum waned by the end of the year.
January 07, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals received FDA approval for Casgevy, a CRSPR-based gene therapy for sickle cell anemia, marking a significant milestone in gene-editing. However, the sector's momentum slowed by the end of 2024.
The FDA approval of Casgevy is a significant achievement for Vertex Pharmaceuticals, likely boosting investor confidence and potentially increasing stock value. However, the overall slowdown in the gene-editing sector by year-end may temper immediate gains.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80